ArticlePharmaceuticals (Basel, Switzerland)2025

Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma.

Linbin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.